Posted by Michael Wonder on 03 Aug 2022
AnHeart Therapeutics receives FDA breakthrough therapy designation for taletrectinib in ROS1 positive non-small-cell lung cancer
3 August 2022 - FDA breakthrough designation reinforces significant unmet need in the treatment of this highly aggressive cancer.
AnHeart Therapeutics today announced that the U.S. FDA has granted breakthrough therapy designation to its investigational ROS1 inhibitor taletrectinib for the treatment of adult patients with advanced or metastatic ROS1 positive non-small-cell lung cancer who are ROS1 tyrosine kinase inhibitor treatment naïve or previously treated with crizotinib.
